Precision Drilling
PDS
Lantheus
LNTH
Dorian LPG
LPG
Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
(FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q3)Sep 30, 2021 | (Q2)Jun 30, 2021 | (Q1)Mar 31, 2021 | (FY)Dec 31, 2020 | (Q4)Dec 31, 2020 | (Q3)Sep 30, 2020 | (Q2)Jun 30, 2020 | (Q1)Mar 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 52.43%2.99T | 62.56%879.45B | 51.42%801.99B | 79.84%707.98B | 20.63%596.76B | -18.84%1.96T | -9.19%541.01B | -16.83%529.65B | -35.76%393.68B | -12.96%494.69B |
Operating revenue | 52.43%2.99T | 62.56%879.45B | 51.42%801.99B | 79.84%707.98B | 20.63%596.76B | -18.84%1.96T | -9.19%541.01B | -16.83%529.65B | -35.76%393.68B | -12.96%494.69B |
Cost of revenue | 43.73%1.41T | 69.86%445.54B | 51.35%388.52B | 62.15%325.64B | -4.75%245.78B | -11.52%977.86B | -9.71%262.29B | -14.81%256.7B | -25.75%200.83B | 6.25%258.04B |
Gross profit | 61.10%1.58T | 55.68%433.9B | 51.48%413.47B | 98.26%382.35B | 48.31%350.98B | -25.02%981.16B | -8.69%278.71B | -18.65%272.95B | -43.67%192.85B | -27.29%236.65B |
Operating expense | 21.94%1.02T | 22.90%261.42B | 18.92%257.24B | 33.64%246.44B | 14.24%254.26B | -3.02%835.98B | -1.18%212.71B | -0.07%216.31B | -15.98%184.4B | 5.57%222.56B |
Selling and administrative expenses | 14.15%132.33B | 10.37%37.96B | 12.32%32.24B | 26.12%32.37B | 9.55%29.76B | -7.70%115.93B | -2.29%34.39B | -11.39%28.7B | -20.94%25.67B | 6.36%27.16B |
-General and administrative expense | 14.15%132.33B | 10.37%37.96B | 12.32%32.24B | 26.12%32.37B | 9.55%29.76B | -7.70%115.93B | -2.29%34.39B | -11.39%28.7B | -20.94%25.67B | 6.36%27.16B |
Other operating expenses | 23.19%887.03B | 25.32%223.46B | 19.93%225B | 34.86%214.07B | 14.90%224.51B | -2.22%720.06B | -0.96%178.31B | 1.92%187.61B | -15.13%158.74B | 5.46%195.4B |
Operating profit | 286.66%561.34B | 161.33%172.49B | 175.86%156.23B | 1,509.09%135.9B | 586.35%96.71B | -67.49%145.18B | -26.67%66.01B | -52.43%56.64B | -93.12%8.45B | -87.71%14.09B |
Net non-operating interest income expense | 59.31%-7.07B | 144.98%2.76B | 80.25%-981M | 18.45%-3.29B | -150.59%-5.56B | -76.04%-17.37B | -461.70%-6.15B | -181.31%-4.97B | -39.54%-4.04B | 46.07%-2.22B |
Non-operating interest income | 128.17%17.97B | 514.95%7.91B | 155.74%4.63B | -7.59%3.35B | -52.09%2.08B | -55.78%7.88B | -824.71%-1.91B | -70.03%1.81B | -43.47%3.62B | -14.64%4.35B |
Non-operating interest expense | -10.84%25.63B | -25.89%5.74B | -17.18%5.62B | -13.32%6.64B | 16.35%7.64B | -12.28%28.75B | 19.98%7.74B | -13.22%6.78B | -17.65%7.66B | -28.68%6.57B |
Total other finance cost | 83.12%-591M | ---- | ---- | ---- | ---- | 31.27%-3.5B | ---- | ---- | ---- | ---- |
Other net income (expense) | ||||||||||
Special income (charges) | -39.66%-11.55B | ---- | ---- | ---- | ---- | 29.17%-8.27B | ---- | ---- | ---- | ---- |
-Less:Other special charges | 39.66%11.55B | ---- | ---- | ---- | ---- | -29.17%8.27B | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | -3,577.61%-16.92B | -121.06%-1.81B | -117.77%-7.84B | 23.47%-2.94B | -166.79%-4.32B | 96.04%-460M | 112.86%8.6B | 31.53%-3.6B | 10.98%-3.84B | 73.35%-1.62B |
Income before tax | 341.18%632.97B | 92.34%186.88B | 419.57%174.9B | 553.93%165.98B | 925.83%105.2B | -71.75%143.47B | -6.35%97.17B | -74.89%33.66B | -81.52%25.38B | -109.61%-12.74B |
Income tax | 397.46%113.6B | 161.26%35.46B | 700.40%30.13B | 424.55%29.44B | 16,390.35%18.57B | -73.37%22.84B | -26.30%13.57B | -83.47%3.76B | -77.18%5.61B | -100.57%-114M |
Net income | 330.53%519.36B | 81.15%151.42B | 384.22%144.77B | 590.67%136.54B | 786.19%86.63B | -71.42%120.63B | -2.05%83.59B | -73.14%29.9B | -82.47%19.77B | -111.21%-12.63B |
Net income continuous Operations | 330.53%519.36B | 81.15%151.42B | 384.22%144.77B | 590.67%136.54B | 786.19%86.63B | -71.42%120.63B | -2.05%83.59B | -73.14%29.9B | -82.47%19.77B | -111.21%-12.63B |
Minority interest income | 442.54%15.92B | 137.12%4.94B | 160.09%5.04B | 252.49%3.46B | 109.65%2.48B | -86.59%2.93B | -59.19%2.09B | -69.57%1.94B | -140.27%-2.27B | -75.28%1.18B |
Net income attributable to the parent company | 327.74%503.45B | 79.71%146.48B | 399.75%139.73B | 503.86%133.08B | 709.56%84.16B | -70.59%117.7B | 1.59%81.51B | -73.35%27.96B | -79.43%22.04B | -112.80%-13.81B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 327.74%503.45B | 79.71%146.48B | 399.75%139.73B | 503.86%133.08B | 709.56%84.16B | -70.59%117.7B | 1.59%81.51B | -73.35%27.96B | -79.43%22.04B | -112.80%-13.81B |
Basic earnings per share | 327.70%533.55 | 79.69%155.25 | 399.49%148.1 | 504.07%141.05 | 708.87%89.2 | -70.58%124.75 | 1.65%86.4 | -73.34%29.65 | -79.44%23.35 | -112.81%-14.65 |
Diluted earnings per share | 327.70%533.55 | 79.69%155.25 | 399.49%148.1 | 504.07%141.05 | 708.87%89.2 | -70.58%124.75 | 1.65%86.4 | -73.34%29.65 | -79.44%23.35 | -112.81%-14.65 |
Dividend per share | 94.71%237.2614 | 666.51%188.3699 | 0 | -49.74%48.8915 | 0 | -6.48%121.8525 | -72.85%24.575 | 0 | 144.56%97.2775 | 0 |
Currency Unit | RUB | RUB | RUB | RUB | RUB | RUB | RUB | RUB | RUB | RUB |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |